Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Brainstorm Cell Therapeutics Inc. (BCLI)
USD0.97
+0.01 (+1.33%)
US OTC Healthcare Biotechnology
Address
1325 Avenue of Americas 10019
New York City, NY, US
New York City, NY, US
CEO
Chaim Lebovits
Website
brainstorm-cell.com
IPO
2003-10-07
CIK 1137883 ISIN US10501E3009
Description
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.97
+0.01 (+1.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11.1K
Beta
0.28
Float Shares
7.15M
Free Float %
64.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.57% | -1.43% | -18.06% | +43.75% | +1.47% | +25.45% | -49.26% | -98.33% | -98.63% | -97.96% | -72.73% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
0.97
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-661.60
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-150.7% Q1'26: +57.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +84.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+74.6% Q1'26: +74.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.19× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 750.0K (-100.0%)
|
-366.0K
est: 750.0K (-148.8%)
|
—
est: 20.00M (-100.0%)
|
—
est: 258.00M (-100.0%)
|
426.90M
426.90M – 426.90M
+65.5% YoY
|
445.79M
445.79M – 445.79M
+4.4% YoY
|
32.91M
32.91M – 32.91M
-92.6% YoY
|
50.59M
50.59M – 50.59M
+53.7% YoY
|
| EBITDA |
-13.84M
est: 450.0K (-3,175.1%)
|
-23.09M
est: 450.0K (-5,230.9%)
|
-11.31M
|
-9.75M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-13.95M
est: 450.0K (-3,199.6%)
|
-23.25M
est: 450.0K (-5,267.3%)
|
-11.55M
|
-9.95M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-13.95M
est: -45.40M (+69.3%)
|
-23.25M
est: -70.89M (+67.2%)
|
11.62M
est: -19.46M (+159.7%)
|
-10.31M
est: -14.92M (+30.9%)
|
-9.92M
-9.92M – -9.92M
+33.5% YoY
|
-7.97M
-7.97M – -7.97M
+19.6% YoY
|
-3.61M
-3.61M – -3.61M
+54.7% YoY
|
-648.8K
-648.8K – -648.8K
+82.1% YoY
|
| SGA |
5.77M
est: 1.84M (+212.9%)
|
5.80M
est: 1.84M (+214.3%)
|
7.04M
|
5.78M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-10.05
est: -8.55 (-17.5%)
|
-13.64
est: -13.35 (-2.2%)
|
2.19
est: -2.10 (+204.3%)
|
-1.11
est: -1.61 (+31.1%)
|
-1.07
-1.07 – -1.07
+33.5% YoY
|
-0.86
-0.86 – -0.86
+19.6% YoY
|
-0.39
-0.39 – -0.39
+54.7% YoY
|
-0.07
-0.07 – -0.07
+82.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.98M
OE per share TTM
-0.84
Owner's Yield
-114.02%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
-7,146.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
5
Total invested
1.7K
Insider transactions (90d)
0
Beneficial owners (>5%)
15
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ACC International Holdings Ltd. | 59.56M | 28.80% | 59.56M | — | — | 10.00 | CO | Citizenship or place of organization | 2014-02-06 | ↗ |
| 2 | ACCBT Corp. | 57.01M | 66.90% | 57.01M | — | — | 10.00 | CO | or place of organization | 2008-04-28 | ↗ |
| 3 | ACC International Holdings Ltd. | 57.01M | 66.90% | 57.01M | — | — | 10.00 | CO | or place of organization | 2008-04-28 | ↗ |
| 4 | Chaim Lebovits | 57.01M | 66.90% | 57.01M | — | — | 10.00 | IN | or place of organization | 2008-04-28 | ↗ |
| 5 | Armistice Capital, LLC | 8.08M | 9.99% | — | 8.08M | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 6 | Steven Boyd | 8.08M | 9.99% | — | 8.08M | — | — | HC, IN | United States of America | 2024-11-14 | ↗ |
| 7 | Kevin D. Ness | 3.30M | 9.10% | 3.30M | — | 3.30M | — | IN | Canada | 2022-02-04 | ↗ |
| 8 | Abbhi Investments, LLC | 2.43M | 6.69% | 2.43M | — | 2.43M | — | OO | Florida | 2022-02-14 | ↗ |
| 9 | Sankesh Abbhi | 2.43M | 6.69% | 2.43M | — | 2.43M | — | IN | Florida | 2022-02-14 | ↗ |
| 10 | Joseph P Daly | 1.08M | 3.66% | 1.08M | — | 1.08M | — | IN | — | 2020-05-08 | ↗ |
| 11 | only). | 635.1K | 4.10% | 368.5K | — | 368.5K | — | IN | United States | 2015-02-12 | ↗ |
| 12 | (1) BlackRock, Inc. | 474.3K | 1.30% | 474.3K | — | 474.3K | — | HC | Delaware | 2021-07-12 | ↗ |
| 13 | Matthew J. Ruck | 275.8K | 5.18% | 275.8K | — | — | — | IN | Gaithersburg, Maryland, United States | 2024-11-13 | ↗ |
| 14 | EssigPR Inc. | 165.0K | 0.56% | 165.0K | — | 165.0K | — | CO | — | 2020-05-08 | ↗ |
| 15 | Karina Daly | 110.0K | 0.37% | 110.0K | — | 110.0K | — | IN | — | 2020-05-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
5
-28 vs prev Q
New positions
0
Closed positions
28
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ADVISOR GROUP HOLDINGS, INC. | — -1.8K (-100.0%) | — -1.4K (-100.0%) | 0.00% -0.021 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 2 | BANGOR SAVINGS BANK | — -266.0 (-100.0%) | — -188.0 (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 3 | ST GERMAIN D J CO INC | — -33.0 (-100.0%) | — -23.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 4 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | — -113.0 (-100.0%) | — -80.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 5 | VSM WEALTH ADVISORY, LLC | — -120.0 (-100.0%) | — -85.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
11
Sells
0
Shares acquired
439.3K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+439,332
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-01 | Yablonka Uri | Director / Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 68,464 | D | ↗ |
| 2025-01-01 | Polverino Anthony J. | Director | A-Award | A | Common Stock | 24,000 | 0.00 | — | 25,730 | D | ↗ |
| 2025-01-01 | Patlis Alla | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 44,349 | D | ↗ |
| 2025-01-01 | Naor Nir | Director | A-Award | A | Common Stock | 30,666 | 0.00 | — | 31,465 | D | ↗ |
| 2025-01-01 | Lindborg Stacy | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 48,229 | D | ↗ |
| 2025-01-01 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 120,000 | 0.00 | — | 200,960 | D | ↗ |
| 2025-01-01 | HARTOUNIAN HARTOUN | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 52,000 | D | ↗ |
| 2025-01-01 | FRENKEL JACOB A | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 43,777 | D | ↗ |
| 2025-01-01 | Dagher Ibrahim B. | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 66,849 | D | ↗ |
| 2025-01-01 | Bairu Menghisteab | Director | A-Award | A | Common Stock | 24,000 | 0.00 | — | 24,000 | D | ↗ |
| 2025-01-01 | ARBEL IRIT | Director | A-Award | A | Common Stock | 30,666 | 0.00 | — | 41,054 | D | ↗ |
| 2024-10-01 | Lebovits Chaim | Officer | P-Purchase | A | Common Stock | 1,836 | 3.43 | 6.3K | 80,960 | D | ↗ |
| 2024-09-30 | Lebovits Chaim | Officer | P-Purchase | A | Common Stock | 22,000 | 0.23 | 5.0K | 1,186,865 | D | ↗ |
| 2024-07-19 | Dagher Ibrahim B. | Officer | S-Sale | D | Common Stock | 63,000 | 0.35 | 22.1K | 0 | — | ↗ |
| 2024-06-24 | HARTOUNIAN HARTOUN | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-28 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 15,000 | 0.52 | 7.8K | 1,164,865 | — | ↗ |
| 2024-05-22 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 25,000 | 0.64 | 16.0K | 1,149,865 | — | ↗ |
| 2024-05-21 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 25,000 | 0.58 | 14.5K | 1,124,865 | — | ↗ |
| 2024-05-13 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 10,000 | 0.49 | 4.9K | 1,099,865 | — | ↗ |
| 2024-05-11 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 10,000 | 0.47 | 4.7K | 1,089,865 | — | ↗ |
| 2024-05-10 | Lebovits Chaim | Officer | P-Purchase | A | Common Stock | 20,000 | 0.47 | 9.3K | 1,079,865 | — | ↗ |
| 2024-05-07 | Lebovits Chaim | Officer | P-Purchase | A | Common Stock | 66,300 | 0.37 | 24.8K | 1,059,865 | — | ↗ |
| 2024-05-06 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 135,000 | 0.38 | 50.7K | 993,565 | — | ↗ |
| 2024-04-19 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 15,000 | 0.52 | 7.8K | 858,565 | — | ↗ |
| 2024-04-18 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 115,072 | 0.53 | 60.5K | 843,565 | — | ↗ |
| 2024-04-17 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 130,000 | 0.55 | 70.9K | 728,493 | — | ↗ |
| 2024-04-17 | Dagher Ibrahim B. | Officer | — | I | Common Stock | 0 | 0.00 | — | 30,000 | — | ↗ |
| 2024-03-11 | Yablonka Uri | Director / Officer | A-Award | A | Common Stock | 109,426 | 0.00 | — | 126,969 | — | ↗ |
| 2024-03-11 | Patlis Alla | Officer | A-Award | A | Common Stock | 65,246 | 0.00 | — | 65,246 | — | ↗ |
| 2024-03-11 | Lindborg Stacy | Officer | A-Award | A | Common Stock | 241,935 | 0.00 | — | 423,435 | — | ↗ |
| 2024-03-11 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 305,198 | 0.00 | — | 598,493 | — | ↗ |
| 2023-09-01 | Lindborg Stacy | Officer | P-Purchase | A | Common Stock | 11,500 | 1.77 | 20.4K | 181,500 | — | ↗ |
| 2023-08-02 | Lindborg Stacy | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 170,000 | — | ↗ |
| 2023-08-02 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 31,185 | 0.00 | — | 293,295 | — | ↗ |
| 2023-06-19 | Naor Nir | Director | A-Award | A | Common Stock | 11,999 | 0.00 | — | 11,999 | — | ↗ |
| 2023-05-01 | Taylor Kirk | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-04-20 | Lindborg Stacy | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 135,000 | — | ↗ |
| 2023-04-20 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 262,110 | — | ↗ |
| 2022-12-07 | Lindborg Stacy | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-09-18 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 31,185 | 0.00 | — | 187,110 | — | ↗ |
| 2022-04-06 | FRENKEL JACOB A | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-03-06 | Kern Ralph Dr. | Officer | A-Award | A | Common Stock | 35,885 | 0.00 | — | 223,310 | — | ↗ |
| 2022-02-01 | Polverino Anthony J. | Director | A-Award | A | Common Stock | 3,882 | 0.00 | — | 25,960 | — | ↗ |
| 2021-12-15 | Yablonka Uri | Director | A-Award | A | Stock Option (right to buy) | 13,333 | 0.75 | 10.0K | 13,333 | — | ↗ |
| 2021-12-15 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 77,332 | — | ↗ |
| 2021-12-15 | Polverino Anthony J. | Director | A-Award | A | Common Stock | 2,000 | 0.00 | — | 22,078 | — | ↗ |
| 2021-12-15 | Almenoff June Sherie | Director | A-Award | A | Common Stock | 2,000 | 0.00 | — | 6,000 | — | ↗ |
| 2021-12-15 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 25,333 | 0.75 | 19.0K | 25,333 | — | ↗ |
| 2021-12-10 | Yablonka Uri | Director | A-Award | A | Stock Option (right to buy) | 13,333 | 0.75 | 10.0K | 13,333 | — | ↗ |
| 2021-12-10 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 65,332 | — | ↗ |
| 2021-12-10 | Polverino Anthony J. | Director | A-Award | A | Common Stock | 2,216 | 0.00 | — | 18,078 | — | ↗ |
| 2021-12-10 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 31,185 | 0.00 | — | 155,925 | — | ↗ |
| 2021-12-10 | Kern Ralph Dr. | Officer | A-Award | A | Common Stock | 35,885 | 0.00 | — | 187,425 | — | ↗ |
| 2021-12-10 | FRENKEL JACOB A | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.75 | 37.5K | 50,000 | — | ↗ |
| 2021-12-10 | Almenoff June Sherie | Director | A-Award | A | Common Stock | 2,000 | 0.00 | — | 4,000 | — | ↗ |
| 2021-12-10 | Abbhi Sankesh | Director | A-Award | A | Common Stock | 6,666 | 0.00 | — | 11,323 | — | ↗ |
| 2021-12-10 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 25,333 | 0.75 | 19.0K | 25,333 | — | ↗ |
| 2021-10-28 | Bairu Menghisteab | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-25 | Patlis Alla | Officer | — | D | Option (Right to Buy) | 4,000 | 2.70 | 10.8K | 0 | — | ↗ |
| 2020-12-30 | Shah Preetam | Officer | F-InKind | D | Common Stock | 25,000 | 4.64 | 116.0K | 11,600 | — | ↗ |
| 2020-11-17 | Lindborg Stacy | Officer | P-Purchase | A | Call Option (right to buy) | 200 | 10.00 | 2.0K | 200 | — | ↗ |
| 2020-09-08 | Waclawski Anthony | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2020-07-26 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 31,185 | 0.00 | — | 124,740 | — | ↗ |
| 2020-07-16 | Setboun David | Officer | P-Purchase | A | Common Stock | 5,000 | 12.95 | 64.7K | 55,000 | — | ↗ |
| 2020-07-16 | ACC International Holdings Ltd. | — | S-Sale | D | Common Stock | 7,823 | 13.47 | 105.4K | 67,053 | — | ↗ |
| 2020-07-15 | Abbhi Sankesh | Director | P-Purchase | A | Common Stock | 46,779 | 12.99 | 607.7K | 2,164,530 | — | ↗ |
| 2020-07-15 | ACC International Holdings Ltd. | — | S-Sale | D | Common Stock | 18,430 | 13.12 | 241.7K | 74,876 | — | ↗ |
| 2020-07-13 | ACC International Holdings Ltd. | — | S-Sale | D | Common Stock | 40,000 | 13.52 | 541.0K | 93,306 | — | ↗ |
| 2020-07-10 | ACC International Holdings Ltd. | — | S-Sale | D | Common Stock | 2,000 | 13.35 | 26.7K | 133,306 | — | ↗ |
| 2020-07-09 | ACC International Holdings Ltd. | — | S-Sale | D | Common Stock | 3,500 | 13.13 | 45.9K | 135,306 | — | ↗ |
| 2020-06-23 | Yablonka Uri | Director / Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 17,543 | — | ↗ |
| 2020-06-01 | Lindborg Stacy | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2020-04-07 | Setboun David | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2020-04-06 | FRENKEL JACOB A | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.75 | 37.5K | 50,000 | — | ↗ |
| 2020-04-06 | Abbhi Sankesh | Director | A-Award | A | Common Stock | 4,657 | 0.00 | — | 4,657 | — | ↗ |
| 2020-03-30 | FRENKEL JACOB A | Director | — | D | Common Stock | 0 | 0.00 | — | 56,667 | — | ↗ |
| 2020-03-30 | Abbhi Sankesh | Director | — | I | Common Stock | 0 | 0.00 | — | 2,117,751 | — | ↗ |
| 2020-03-09 | Kern Ralph Dr. | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 7.33 | 586.4K | 80,000 | — | ↗ |
| 2020-03-06 | Kern Ralph Dr. | Officer | A-Award | A | Common Stock | 35,885 | 0.00 | — | 151,540 | — | ↗ |
| 2020-03-06 | Abbhi Sankesh | Director | — | I | Warrant to Purchase Common Stock | 250,000 | 15.00 | 3.75M | 0 | — | ↗ |
| 2020-02-01 | Polverino Anthony J. | Director | A-Award | A | Common Stock | 3,071 | 0.00 | — | 15,862 | — | ↗ |
| 2019-12-24 | Shah Preetam | Officer | P-Purchase | A | Common Stock | 11,600 | 3.96 | 45.9K | 36,600 | — | ↗ |
| 2019-12-24 | Kern Ralph Dr. | Officer | P-Purchase | A | Common Stock | 3,000 | 3.88 | 11.6K | 115,655 | — | ↗ |
| 2019-12-24 | Araya Arturo | Officer | P-Purchase | A | Common Stock | 3,000 | 3.90 | 11.7K | 8,608 | — | ↗ |
| 2019-12-12 | Yablonka Uri | Director / Officer | A-Award | A | Stock Option (right to buy) | 13,333 | 0.75 | 10.0K | 13,333 | — | ↗ |
| 2019-12-12 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 53,332 | — | ↗ |
| 2019-12-12 | Polverino Anthony J. | Director | A-Award | A | Common Stock | 2,000 | 0.00 | — | 12,791 | — | ↗ |
| 2019-12-12 | Almenoff June Sherie | Director | A-Award | A | Common Stock | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2019-12-12 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 25,333 | 0.75 | 19.0K | 25,333 | — | ↗ |
| 2019-09-06 | Shah Preetam | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 6.00 | 600.0K | 100,000 | — | ↗ |
| 2019-08-28 | ARBEL IRIT | Director | M-Exempt | A | Common Stock | 6,666 | 2.25 | 15.0K | 169,165 | — | ↗ |
| 2019-07-26 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 31,185 | 0.00 | — | 2,166,155 | — | ↗ |
| 2019-03-06 | Kern Ralph Dr. | Officer | A-Award | A | Common Stock | 35,885 | 0.00 | — | 112,655 | — | ↗ |
| 2019-02-01 | Polverino Anthony J. | Director | A-Award | A | Common Stock | 3,501 | 0.00 | — | 10,791 | — | ↗ |
| 2019-01-04 | Almenoff June Sherie | Director | P-Purchase | A | Common Stock | 1,475 | 3.39 | 5.0K | 7,175 | — | ↗ |
| 2018-11-30 | Yablonka Uri | Director / Officer | A-Award | A | Stock Option (right to buy) | 13,333 | 0.75 | 10.0K | 13,333 | — | ↗ |
| 2018-11-30 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 41,332 | — | ↗ |
| 2018-11-30 | Schor Chen | Director | A-Award | A | Common Stock | 2,000 | 0.00 | — | 125,558 | — | ↗ |
| 2018-11-30 | Polverino Anthony J. | Director | A-Award | A | Common Stock | 1,667 | 0.00 | — | 7,290 | — | ↗ |
| 2018-11-30 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 25,333 | 0.75 | 19.0K | 25,333 | — | ↗ |
| 2018-10-24 | Schor Chen | Director | G-Gift | A | Common Stock | 121,558 | 0.00 | — | 121,558 | — | ↗ |
| 2018-08-28 | Araya Arturo | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 3.98 | 796.0K | 200,000 | — | ↗ |
| 2018-07-26 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 31,185 | 0.00 | — | 2,134,970 | — | ↗ |
| 2018-03-26 | Araya Arturo | Director | A-Award | A | Common Stock | 1,249 | 0.00 | — | 8,413 | — | ↗ |
| 2018-03-15 | Kern Ralph Dr. | Officer | A-Award | A | Common Stock | 5,000 | 3.60 | 18.0K | 40,885 | — | ↗ |
| 2018-03-15 | Almenoff June Sherie | Director | A-Award | A | Common Stock | 5,700 | 3.50 | 20.0K | 5,700 | — | ↗ |
| 2018-03-06 | Kern Ralph Dr. | Officer | A-Award | A | Common Stock | 35,885 | 0.00 | — | 76,770 | — | ↗ |
| 2018-02-26 | Araya Arturo | Director | A-Award | A | Common Stock | 4,152 | 0.00 | — | 7,164 | — | ↗ |
| 2018-02-01 | Polverino Anthony J. | Director | A-Award | A | Common Stock | 3,623 | 0.00 | — | 3,623 | — | ↗ |
| 2017-11-20 | Rubin Eyal | Officer | A-Award | A | Stock Option (right to buy) | 93,686 | 4.30 | 402.8K | 93,686 | — | ↗ |
| 2017-11-10 | Yablonka Uri | Director / Officer | A-Award | A | Stock Option (right to buy) | 13,333 | 0.75 | 10.0K | 13,333 | — | ↗ |
| 2017-11-10 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 12,000 | 0.00 | — | 29,332 | — | ↗ |
| 2017-11-10 | Schor Chen | Director | A-Award | A | Common Stock | 2,000 | 0.00 | — | 123,558 | — | ↗ |
| 2017-11-10 | SHORR ROBERT G L | Director | A-Award | A | Common Stock | 8,666 | 0.00 | — | 45,731 | — | ↗ |
| 2017-11-10 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 25,333 | 0.75 | 19.0K | 25,333 | — | ↗ |
| 2017-08-31 | ARBEL IRIT | Director | P-Purchase | A | Common Stock | 2,500 | 4.26 | 10.7K | 155,833 | — | ↗ |
| 2017-08-23 | Yablonka Uri | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 3.98 | 8.0K | 7,543 | — | ↗ |
| 2017-07-26 | Lebovits Chaim | Officer | A-Award | A | Common Stock | 31,185 | 0.00 | — | 2,103,785 | — | ↗ |
| 2017-07-13 | Yablonka Uri | Director / Officer | A-Award | A | Common Stock | 5,543 | 0.00 | — | 5,543 | — | ↗ |
| 2017-07-13 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 0.75 | 9.0K | 12,000 | — | ↗ |
| 2017-03-06 | Kern Ralph Dr. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-02-26 | Araya Arturo | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-02-26 | Almenoff June Sherie | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-02-26 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 6,667 | 0.75 | 5.0K | 6,667 | — | ↗ |
| 2016-11-14 | Patlis Alla | Officer | — | D | Option (right to buy) granted on December 31, 2013 | 4,000 | 2.70 | 10.8K | 0 | — | ↗ |
| 2016-06-22 | Yablonka Uri | Director / Officer | A-Award | A | Stock Option (right to buy) | 13,333 | 0.75 | 10.0K | 13,333 | — | ↗ |
| 2016-06-22 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 8,666 | 0.00 | — | 17,332 | — | ↗ |
| 2016-06-22 | SHORR ROBERT G L | Director | A-Award | A | Common Stock | 8,666 | 0.00 | — | 37,065 | — | ↗ |
| 2016-06-22 | Pinkas Alon | Director | A-Award | A | Stock Option (right to buy) | 15,333 | 0.75 | 11.5K | 15,333 | — | ↗ |
| 2016-06-22 | Friedman Mordechai | Director | A-Award | A | Stock Option (right to buy) | 16,666 | 0.75 | 12.5K | 16,666 | — | ↗ |
| 2016-06-22 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 25,333 | 0.75 | 19.0K | 25,333 | — | ↗ |
| 2015-12-16 | SHORR ROBERT G L | Director | S-Sale | D | Common Stock | 10,800 | 2.71 | 29.3K | 28,399 | — | ↗ |
| 2015-12-15 | TAUB MALCOLM S | Director | S-Sale | D | Common Stock | 11,263 | 2.59 | 29.2K | 8,666 | — | ↗ |
| 2015-12-14 | TAUB MALCOLM S | Director | S-Sale | D | Common Stock | 30,479 | 2.61 | 79.6K | 19,929 | — | ↗ |
| 2015-12-14 | Friedman Mordechai | Director | M-Exempt | D | Stock Option (right to buy) | 5,000 | 0.75 | 3.8K | 11,666 | — | ↗ |
| 2015-12-11 | TAUB MALCOLM S | Director | S-Sale | D | Common Stock | 980 | 2.66 | 2.6K | 50,408 | — | ↗ |
| 2015-12-11 | SHORR ROBERT G L | Director | S-Sale | D | Common Stock | 5,300 | 2.56 | 13.6K | 39,199 | — | ↗ |
| 2015-12-10 | TAUB MALCOLM S | Director | S-Sale | D | Common Stock | 12,500 | 2.74 | 34.3K | 51,388 | — | ↗ |
| 2015-12-10 | SHORR ROBERT G L | Director | S-Sale | D | Common Stock | 5,500 | 2.71 | 14.9K | 44,499 | — | ↗ |
| 2015-12-01 | Bibring Yoram | Officer | D-Return | A | Stock Option (right to buy) | 82,500 | 3.17 | 261.5K | 82,500 | — | ↗ |
| 2015-10-01 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 2,000 | 2.58 | 5.2K | 138,806 | — | ↗ |
| 2015-09-30 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 9,200 | 2.34 | 21.5K | 136,806 | — | ↗ |
| 2015-09-28 | Lebovits Chaim | Officer | A-Award | A | Stock Option (right to buy) | 369,619 | 2.45 | 905.6K | 369,619 | — | ↗ |
| 2015-08-27 | Yablonka Uri | Director / Officer | A-Award | A | Stock Option (right to buy) | 13,333 | 0.75 | 10.0K | 13,333 | — | ↗ |
| 2015-08-27 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 8,666 | 0.00 | — | 50,554 | — | ↗ |
| 2015-08-27 | SHORR ROBERT G L | Director | A-Award | A | Common Stock | 8,666 | 0.00 | — | 49,999 | — | ↗ |
| 2015-08-27 | Pinkas Alon | Director | A-Award | A | Stock Option (right to buy) | 15,333 | 0.75 | 11.5K | 15,333 | — | ↗ |
| 2015-08-27 | Friedman Mordechai | Director | A-Award | A | Stock Option (right to buy) | 16,666 | 0.75 | 12.5K | 16,666 | — | ↗ |
| 2015-08-27 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 25,333 | 0.75 | 19.0K | 25,333 | — | ↗ |
| 2015-08-20 | Bibring Yoram | Officer | P-Purchase | A | Common Stock | 8,500 | 3.04 | 25.8K | 50,000 | — | ↗ |
| 2015-08-17 | Bibring Yoram | Officer | P-Purchase | A | Common Stock | 41,500 | 2.92 | 121.2K | 41,500 | — | ↗ |
| 2015-07-30 | Bibring Yoram | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-06-01 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 6,667 | 0.75 | 5.0K | 6,667 | — | ↗ |
| 2015-05-13 | Patlis Alla | Officer | — | D | Option (right to buy) granted on December 31, 2013 | 4,000 | 2.70 | 10.8K | 0 | — | ↗ |
| 2015-05-03 | Schor Chen | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 121,558 | — | ↗ |
| 2014-10-15 | Fiorino Anthony S. | Officer | P-Purchase | A | Common Stock | 300 | 3.60 | 1.1K | 2,500 | — | ↗ |
| 2014-10-10 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 600 | 4.01 | 2.4K | 124,206 | — | ↗ |
| 2014-10-01 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 3,600 | 4.08 | 14.7K | 119,006 | — | ↗ |
| 2014-09-30 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 1,000 | 4.32 | 4.3K | 115,406 | — | ↗ |
| 2014-09-29 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 100 | 4.18 | 418.00 | 112,406 | — | ↗ |
| 2014-09-22 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 400 | 4.28 | 1.7K | 108,506 | — | ↗ |
| 2014-09-19 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 1,000 | 3.94 | 3.9K | 103,806 | — | ↗ |
| 2014-09-18 | Fiorino Anthony S. | Officer | P-Purchase | A | Common Stock | 800 | 3.84 | 3.1K | 2,000 | — | ↗ |
| 2014-09-15 | Fiorino Anthony S. | Officer | P-Purchase | A | Common Stock | 3,000 | 0.28 | 850.50 | 18,000 | — | ↗ |
| 2014-09-12 | Fiorino Anthony S. | Officer | P-Purchase | A | Common Stock | 7,500 | 0.29 | 2.1K | 10,000 | — | ↗ |
| 2014-08-15 | Yablonka Uri | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.05 | 10.0K | 200,000 | — | ↗ |
| 2014-08-15 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 130,000 | 0.00 | — | 628,333 | — | ↗ |
| 2014-08-15 | SHORR ROBERT G L | Director | A-Award | A | Common Stock | 130,000 | 0.00 | — | 620,000 | — | ↗ |
| 2014-08-15 | Pinkas Alon | Director | A-Award | A | Stock Option (right to buy) | 230,000 | 0.05 | 11.5K | 230,000 | — | ↗ |
| 2014-08-15 | Friedman Mordechai | Director | A-Award | A | Stock Option (right to buy) | 250,000 | 0.05 | 12.5K | 250,000 | — | ↗ |
| 2014-08-15 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 380,000 | 0.05 | 19.0K | 380,000 | — | ↗ |
| 2014-06-16 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 130,000 | 0.29 | 37.7K | 1,519,600 | — | ↗ |
| 2014-06-13 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 150,000 | 0.35 | 52.5K | 1,389,600 | — | ↗ |
| 2014-06-09 | Fiorino Anthony S. | Officer | A-Award | A | Stock Option (right to buy) | 5,700,000 | 0.30 | 1.71M | 5,700,000 | — | ↗ |
| 2014-06-06 | Yablonka Uri | Director / Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 0.18 | 90.0K | 500,000 | — | ↗ |
| 2014-04-28 | ACC International Holdings Ltd. | — | P-Purchase | A | Common Stock | 939,600 | 0.30 | 281.9K | 1,239,600 | — | ↗ |
| 2014-04-13 | Israeli Avi | Director | A-Award | A | Stock Option (right to buy) | 166,666 | 0.00 | — | 166,666 | — | ↗ |
| 2014-01-24 | Natanson Alon | Officer | — | D | Stock Option (right to buy) | 4,000,000 | 0.29 | 1.16M | 0 | — | ↗ |
| 2013-12-31 | Sossover Liat | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.18 | 18.0K | 100,000 | — | ↗ |
| 2013-04-19 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 130,000 | 0.00 | — | 498,333 | — | ↗ |
| 2013-04-19 | SHORR ROBERT G L | Director | A-Award | A | Common Stock | 130,000 | 0.00 | — | 490,000 | — | ↗ |
| 2013-04-19 | Pinkas Alon | Director | A-Award | A | Stock Option (right to buy) | 130,000 | 0.15 | 19.5K | 130,000 | — | ↗ |
| 2013-04-19 | Friedman Mordechai | Director | A-Award | A | Stock Option (right to buy) | 150,000 | 0.15 | 22.5K | 150,000 | — | ↗ |
| 2013-04-19 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 0.15 | 27.0K | 180,000 | — | ↗ |
| 2013-04-13 | Israeli Avi | Director | A-Award | A | Stock Option (right to buy) | 166,666 | 0.00 | — | 166,666 | — | ↗ |
| 2012-08-01 | TAUB MALCOLM S | Director | A-Award | A | Common Stock | 130,000 | 0.00 | — | 368,333 | — | ↗ |
| 2012-08-01 | Sossover Liat | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 0.26 | 15.6K | 60,000 | — | ↗ |
| 2012-08-01 | SHORR ROBERT G L | Director | A-Award | A | Common Stock | 130,000 | 0.00 | — | 360,000 | — | ↗ |
| 2012-08-01 | Pinkas Alon | Director | A-Award | A | Stock Option (right to buy) | 130,000 | 0.15 | 19.5K | 130,000 | — | ↗ |
| 2012-08-01 | Harel Adrian | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 0.26 | 18.2K | 70,000 | — | ↗ |
| 2012-08-01 | Friedman Mordechai | Director | A-Award | A | Stock Option (right to buy) | 150,000 | 0.15 | 22.5K | 150,000 | — | ↗ |
| 2012-08-01 | ARBEL IRIT | Director | A-Award | A | Stock Option (right to buy) | 180,000 | 0.15 | 27.0K | 180,000 | — | ↗ |
| 2012-04-13 | Israeli Avi | Director | A-Award | A | Stock Option (right to buy) | 166,666 | 0.00 | — | 166,666 | — | ↗ |
| 2011-12-05 | SHORR ROBERT G L | Director | S-Sale | D | Common Stock | 98,333 | 0.26 | 25.1K | 230,000 | — | ↗ |
| 2011-11-28 | SHORR ROBERT G L | Director | S-Sale | D | Common Stock | 10,000 | 0.27 | 2.7K | 328,333 | — | ↗ |
| 2011-10-21 | Schor Chen | Director | A-Award | A | Common Stock | 923,374 | 0.00 | — | 923,374 | — | ↗ |
| 2011-10-05 | SHORR ROBERT G L | Director | S-Sale | D | Common Stock | 95,000 | 0.30 | 28.9K | 338,333 | — | ↗ |
| 2011-10-04 | SHORR ROBERT G L | Director | S-Sale | D | Common Stock | 105,000 | 0.31 | 32.9K | 433,333 | — | ↗ |
| 2011-08-22 | Schor Chen | Director | A-Award | A | Common Stock | 923,374 | 0.00 | — | 923,374 | — | ↗ |
| 2011-08-10 | Harel Adrian | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 0.20 | 14.0K | 70,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
11.03M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Chaim Lebovits , Chief Executive Officer & President | 387.5K | 121.7K | 100.7K | — | — | 140.4K | 750.3K | 13.42% | ↗ |
| 2 | 2024 | Dr. Ibrahim B. Dagher , Executive Vice President, Chief Medical Officer | 294.0K | 103.8K | 71.9K | — | — | 29.0K | 498.6K | 14.41% | ↗ |
| 3 | 2024 | Stacy Lindborg, Former Co-Chief Executive Officer | 125.9K | 100.0K | 79.8K | — | — | 40.6K | 346.4K | 23.05% | ↗ |
| 4 | 2024 | Uri Yablonka , Executive Vice President, Chief Business Officer, Secretary and Director | 151.4K | — | 36.1K | — | — | 78.6K | 266.1K | 13.57% | ↗ |
| 5 | 2023 | Chaim Lebovits , Chief Executive Officer & President | 441.7K | 250.0K | 250.0K | — | — | 187.1K | 1.13M | 22.15% | ↗ |
| 6 | 2023 | Chaim Lebovits , Co-Chief Executive Officer & President | 441.7K | 250.0K | 250.0K | — | — | 187.1K | 1.13M | 22.15% | ↗ |
| 7 | 2023 | Stacy Lindborg, Co-Chief Executive Officer | 475.0K | 200.0K | 256.7K | — | — | 76.1K | 1.01M | 25.47% | ↗ |
| 8 | 2023 | Stacy Lindborg, Former Co-Chief Executive Officer | 475.0K | 200.0K | 256.7K | — | — | 76.1K | 1.01M | 25.47% | ↗ |
| 9 | 2023 | Ralph Kern, Former President & Former Chief Medical Officer | 29.5K | 125.0K | 671.4K | — | — | 7.2K | 833.2K | 80.59% | ↗ |
| 10 | 2023 | Uri Yablonka , Executive Vice President, Chief Business Officer, Secretary and Director | 164.8K | — | — | — | — | 82.3K | 247.1K | 0.00% | ↗ |
| 11 | 2023 | Alla Patlis , Interim Chief Financial Officer and Controller | 98.3K | — | 15.9K | — | — | 32.7K | 146.8K | 10.81% | ↗ |
| 12 | 2022 | Chaim Lebovits , President & Chief Executive Officer | 500.0K | 3.00 | 127.5K | — | — | 240.4K | 1.12M | 11.41% | ↗ |
| 13 | 2022 | Chaim Lebovits , Co-Chief Executive Officer & President | 500.0K | 250.0K | 127.5K | — | — | 240.4K | 1.12M | 11.41% | ↗ |
| 14 | 2022 | Stacy Lindborg, Co-Chief Executive Officer | 469.0K | 164.2K | 143.2K | — | — | 75.2K | 851.5K | 16.81% | ↗ |
| 15 | 2022 | Ralph Kern, Former President & Former Chief Medical Officer | 500.0K | 150.0K | 106.2K | — | — | 56.3K | 812.6K | 13.07% | ↗ |
| 16 | 2021 | Chaim Lebovits , Chief Executive Officer | 500.0K | 250.0K | 110.4K | — | — | 268.0K | 1.13M | 9.78% | ↗ |
| 17 | 2021 | Chaim Lebovits , President & Chief Executive Officer | 500.0K | 4.00 | 110.4K | — | — | 268.0K | 1.13M | 9.78% | ↗ |
| 18 | 2021 | Ralph Kern, Former President & Former Chief Medical Officer | 500.0K | 6.00 | 126.0K | — | — | 62.9K | 938.8K | 13.42% | ↗ |
| 19 | 2021 | Ralph Kern, President & Chief Medical Officer | 500.0K | 250.0K | 126.0K | — | — | 62.9K | 938.8K | 13.42% | ↗ |
| 20 | 2021 | Stacy Lindborg, Co-Chief Executive Officer | 469.0K | 9.00 | — | — | — | 78.5K | 736.7K | 0.00% | ↗ |
| 21 | 2021 | Stacy Lindborg, EVP, Chief Development Officer | 469.0K | 189.2K | — | — | — | 78.5K | 736.7K | 0.00% | ↗ |
| 22 | 2020 | Chaim Lebovits , Chief Executive Officer | 500.0K | 860.0K | 486.2K | — | — | 279.7K | 2.13M | 22.87% | ↗ |
| 23 | 2020 | Ralph Kern, President & Chief Medical Officer | 500.0K | 290.0K | 273.4K | 410.6K | — | 54.2K | 1.53M | 44.76% | ↗ |
| 24 | 2020 | Anthony Paul Waclawski, Former EVP, Global Head of Regulatory | 87.5K | — | 440.3K | 510.0K | — | 34.0K | 1.07M | 88.67% | ↗ |
| 25 | 2020 | Stacy Lindborg, EVP, Chief Development Officer | 218.8K | 10.0K | 186.3K | 404.4K | — | 48.1K | 867.5K | 68.08% | ↗ |
| 26 | 2019 | Chaim Lebovits , Chief Executive Officer | 500.0K | 250.0K | 125.4K | — | — | 180.9K | 1.06M | 11.87% | ↗ |
| 27 | 2019 | Ralph Kern, Chief Medical Officer | 500.0K | 250.0K | 125.4K | — | — | 180.9K | 1.06M | 11.87% | ↗ |
| 28 | 2019 | Ralph Kern, President & Chief Medical Officer | 500.0K | 150.0K | 139.0K | — | — | 63.1K | 852.1K | 16.31% | ↗ |
| 29 | 2019 | Preetam Shah, Chief Financial Officer | 109.4K | — | 99.0K | 414.8K | — | 23.8K | 646.9K | 79.42% | ↗ |
| 30 | 2018 | Chaim Lebovits Chief Executive Officer | 500.0K | 750.0K | 133.5K | — | — | 195.4K | 1.58M | 8.45% | ↗ |
| 31 | 2018 | Chaim Lebovits President and CEO | 500.0K | 750.0K | 133.5K | — | — | 195.4K | 1.58M | 8.45% | ↗ |
| 32 | 2018 | Ralph Kern, Chief Operating Officer | 500.0K | 150.0K | 119.0K | — | — | 72.7K | 841.7K | 14.14% | ↗ |
| 33 | 2018 | Ralph Kern, Chief Medical Officer | 500.0K | 150.0K | 119.0K | — | — | 72.7K | 841.7K | 14.14% | ↗ |
| 34 | 2018 | Eyal Rubin , Chief Financial Officer | 197.0K | 49.0K | — | — | — | 105.0K | 351.0K | 0.00% | ↗ |
| 35 | 2017 | Chaim Lebovits President and CEO | 391.3K | 250.0K | 193.5K | — | — | 170.6K | 1.01M | 19.25% | ↗ |
| 36 | 2017 | Ralph Kern, Chief Operating Officer | 417.0K | — | 200.0K | — | — | 59.0K | 676.0K | 29.59% | ↗ |
| 37 | 2017 | Eyal Rubin , Chief Financial Officer | 20.2K | 5.0K | 347.8K | — | — | 9.2K | 382.3K | 91.00% | ↗ |
| 38 | 2017 | Uri Yablonka , Executive Vice President, Chief Business Officer | 122.0K | — | 73.5K | — | — | 62.0K | 257.5K | 28.54% | ↗ |
| 39 | 2016 | Chaim Lebovits President and CEO | 282.5K | 141.3K | — | — | — | 130.0K | 553.8K | 0.00% | ↗ |
| 40 | 2016 | Chaim Lebovits President and CEO Tony Fiorino Former CEO Yoram Bibring, Former Chief Financial Officer | 282.5K | 141.3K | — | — | — | 130.0K | 553.8K | 0.00% | ↗ |
| 41 | 2016 | Uri Yablonka , Executive Vice President, Chief Business Officer | 100.0K | — | 27.0K | — | — | 53.0K | 180.0K | 15.00% | ↗ |
| 42 | 2016 | Uri Yablonka EVP & Chief Business Officer Alla Patlis Interim Chief Financial Officer | 99.0K | — | — | — | — | 43.0K | 142.0K | 0.00% | ↗ |
| 43 | 2015 | Chaim Lebovits President and CEO | 75.0K | — | — | 472.0K | — | 29.0K | 576.0K | 81.94% | ↗ |
| 44 | 2015 | Chaim Lebovits President and CEO Tony Fiorino Former CEO Yoram Bibring, Former Chief Financial Officer | 279.0K | — | — | — | — | 54.0K | 333.0K | 0.00% | ↗ |
| 45 | 2015 | Tony Fiorino Former CEO | 279.0K | — | — | — | — | 54.0K | 333.0K | 0.00% | ↗ |
| 46 | 2015 | Yoram Bibring, Chief Financial Officer | 94.0K | — | — | 194.0K | — | 16.0K | 304.0K | 63.82% | ↗ |
| 47 | 2015 | Uri Yablonka Chief Operating Officer | 99.0K | — | — | 33.0K | — | 51.0K | 183.0K | 18.03% | ↗ |
| 48 | 2015 | Liat Sossover Former Chief Financial Officer | 49.0K | — | — | — | — | 46.0K | 95.0K | 0.00% | ↗ |
| 49 | 2015 | Uri Yablonka EVP & Chief Business Officer Alla Patlis Interim Chief Financial Officer | 59.0K | — | — | — | — | 32.0K | 91.0K | 0.00% | ↗ |
| 50 | 2014 | Tony Fiorino Former CEO | 154.0K | — | — | 1.49M | — | 35.0K | 1.68M | 88.77% | ↗ |
| 51 | 2014 | Tony Fiorino, CEO | 154.0K | — | — | 1.49M | — | 35.0K | 1.68M | 88.77% | ↗ |
| 52 | 2014 | Uri Yablonka (*) Chief Operating Officer | 60.0K | — | — | 97.4K | — | 27.0K | 184.4K | 52.82% | ↗ |
| 53 | 2014 | Uri Yablonka Chief Operating Officer | 60.0K | — | — | 97.4K | — | 27.0K | 184.4K | 52.82% | ↗ |
| 54 | 2014 | Liat Sossover Former Chief Financial Officer | 107.0K | — | — | — | — | 67.0K | 174.0K | 0.00% | ↗ |
| 55 | 2014 | Liat Sossover (*) Chief Financial Officer | 107.0K | — | — | — | — | 67.0K | 174.0K | 0.00% | ↗ |
| 56 | 2014 | Chaim Lebovits President | — | — | — | — | — | — | — | — | ↗ |
| 57 | 2013 | Alon Natanson Former Chief Executive Officer | — | — | — | — | — | — | 211.0K | 0.00% | ↗ |
| 58 | 2013 | Adrian Harel Former Director of Research and Development | — | — | — | — | — | — | 211.0K | 0.00% | ↗ |
| 59 | 2013 | Liat Sossover (*) Chief Financial Officer | 106.0K | — | — | 16.0K | — | 65.0K | 187.0K | 8.56% | ↗ |
| 60 | 2013 | Liat Sossover Chief Financial Officer | — | — | — | — | — | — | 187.0K | 0.00% | ↗ |
| 61 | 2013 | Chaim Lebovits President | — | — | — | — | — | — | — | — | ↗ |
| 62 | 2012 | Adrian Harel Director of Research and Development and Former Chief Executive Officer | 121.4K | 60.0K | — | 16.0K | — | 71.3K | 268.7K | 5.96% | ↗ |
| 63 | 2012 | Adrian Harel Former Director of Research and Development | — | — | — | — | — | — | 268.7K | 0.00% | ↗ |
| 64 | 2012 | Liat Sossover Chief Financial Officer | — | — | — | — | — | — | 189.1K | 0.00% | ↗ |
| 65 | 2012 | Alon Natanson Former Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 66 | 2012 | Chaim Lebovits President | — | — | — | — | — | — | — | — | ↗ |
| 67 | 2011 | Adrian Harel Acting Chief Executive Officer | 117.0K | — | — | 203.0K | — | 65.0K | 385.0K | 52.73% | ↗ |
| 68 | 2011 | Adrian Harel Director of Research and Development and Former Chief Executive Officer | 117.0K | — | — | 203.0K | — | 65.0K | 385.0K | 52.73% | ↗ |
| 69 | 2011 | Abraham Efrati Former Chief Executive Officer and Director | 264.0K | — | — | 30.5K | — | 25.0K | 319.5K | 9.54% | ↗ |
| 70 | 2011 | Liat Sossover Chief Financial Officer | 98.0K | — | — | — | — | 46.0K | 144.0K | 0.00% | ↗ |
| 71 | 2011 | Liat Sossover Chief Financial Officer | 98.0K | — | — | — | — | 46.0K | 144.0K | 0.00% | ↗ |
| 72 | 2010 | Abraham Efrati Former Chief Executive Officer and Director | 167.0K | — | — | — | — | 13.0K | 180.0K | 0.00% | ↗ |
| 73 | 2010 | Abraham Efrati Chief Executive Officer and Director | 167.0K | — | — | — | — | 13.0K | 180.0K | 0.00% | ↗ |
| 74 | 2010 | Liat Sossover Chief Financial Officer | 47.0K | — | — | 67.6K | — | 12.0K | 126.6K | 53.39% | ↗ |
| 75 | 2009 | Abraham Efrati Chief Executive Officer and Director | 156.8K | — | — | 252.9K | — | 69.8K | 479.5K | 52.74% | ↗ |
| 76 | 2009 | Abraham Efrati Chief Executive Officer and Director | 156.8K | — | — | 252.9K | — | 69.8K | 479.5K | 52.74% | ↗ |
| 77 | 2009 | David Stolick Chief Financial Officer | 90.7K | — | — | 48.4K | — | 27.6K | 166.7K | 29.02% | ↗ |
| 78 | 2008 | Abraham Efrati Chief Executive Officer and Director | 179.9K | — | — | 246.2K | — | 61.3K | 487.3K | 50.51% | ↗ |
| 79 | 2008 | David Stolick Chief Financial Officer | 104.8K | — | — | 80.2K | — | 40.2K | 225.2K | 35.63% | ↗ |
| 80 | 2007 | Abraham (Rami) Efrati Chief Executive Officer | 39.6K | — | — | 46.1K | — | 11.5K | 97.2K | 47.48% | ↗ |
| 81 | 2007 | Chaim Lebovits President | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chaim Lebovits | President & Chief Executive Officer | 456.5K | male |
| Uri Yablonka | Executive Vice President, Chief Business Officer, Secretary & Director | 199.9K | male |
| Ibrahim Dagher | Executive Vice President & Chief Medical Officer | 161.7K | — |
| Alla Patlis | Interim Chief Financial Officer & Controller | 130.9K | female |
| Hartoun Hartounian | Executive Vice President & Chief Operating Officer | — | — |
| Mary Kay Turner | Senior Vice President of Patient Advocacy & Government Affairs | — | female |
| Netta Blondheim-Shraga | Senior Vice President of Research and Development | — | — |
| Daniel Offen | Chief Scientific Advisor | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BCLI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
